Diamyd awarded three million dollar grant and expands the NTTDS portfolio
Diamyd Medical AB with collaborators has received a three million dollar grant from the US National Institutes of Health to develop the Company’s patented Nerve Targeting Drug Delivery System (NTDDS) for prevention of Chemotherapy Induced Peripheral Neuropathy. The grant allows Diamyd to expand the NTDDS technology to also target neuropathy, in addition to the Company’s development portfolio for the treatment of pain.The three-year grant funds the development of a NTDDS-based drug candidate, engineered to deliver a neurotrophic factor to nerve cells. It is hoped that use of NTDDS to deliver